This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    neomend
Previous Study | Return to List | Next Study

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

This study has been completed.
Information provided by (Responsible Party):
C. R. Bard Identifier:
First received: July 13, 2011
Last updated: June 9, 2017
Last verified: June 2017
The purpose of this post approval study is to further characterize the safety profile of the ProGEL™ Pleural Air Leak Sealant in commercial use, with specific reference to long-term safety over 90 days of follow-up.

Condition Intervention
Lung Cancer Lung Tumor Other: Control Device: ProGEL Pleural Air Leak Sealant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AirTight: A Prospective Controlled Post-Approval Study of NeoMend ProGEL™ Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure

Resource links provided by NLM:

Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Safety Endpoints [ Time Frame: 90 days ]
    • Pulmonary adverse events: pneumothorax, persistent air leak, late onset air leak, residual pleural space, and acute respiratory distress syndrome
    • Renal adverse events
    • Cardiac adverse events
    • Death (all causes)
    • Hospital readmission

Enrollment: 444
Study Start Date: June 2011
Study Completion Date: February 2016
Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No treatment.
Other: Control
Standard surgical techniques including staples and sutures.
Experimental: ProGEL Pleural Air Leak Sealant
Standard surgical technique plus Progel Pleural Air Leak Sealant.
Device: ProGEL Pleural Air Leak Sealant
ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG).

Detailed Description:
Patients having open thoracotomy involving lung resection surgery will be considered for the study. Subjects will be examined for adverse events and complications from either the treatment or the procedure. Follow-up visits are required at 30 days and 90 days after the surgery.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Scheduled for an open thoracotomy for lung resection
  • Has at least one or more intraoperative visible air leak >= 2 mm following the lung resection surgery

Exclusion Criteria:

  • Pregnant or breast feeding
  • History of an allergic reaction to Human Serum Albumin
  • Has a significant clinical disease or condition
  • Had previous open thoracotomy procedures
  • Unable to participate in all necessary study activities due to physical or mental limitations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01394978

United States, Alabama
St. Vincent Birmingham & St. Vincent East
Birmingham, Alabama, United States, 35243
University of Alabama in Birmingham
Birmingham, Alabama, United States, 35894
United States, Florida
Jacksonville Center for Research
Jacksonville, Florida, United States, 32207
Moffit Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
WellStar Research Institute
Atlanta, Georgia, United States, 30060
Emory University
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
St. Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States, 46290
United States, Maryland
Greater Baltimore Medical Center
Baltimore, Maryland, United States, 21204
United States, Massachusetts
Mass General Hospital
Boston, Massachusetts, United States, 02114
Brigham Womens' Hospital
Boston, Massachusetts, United States, 02115
Beth Israel Deconess Medical Center
Boston, Massachusetts, United States, 02215
UMass Memorial Medical
Worcester, Massachusetts, United States, 01605
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Pennsylvania
Lancaster General Hospital
Lancaster, Pennsylvania, United States, 17602
United States, Virginia
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
United States, Wisconsin
Dean Foundation for Health, Research and Education, Inc.
Madison, Wisconsin, United States, 53715
Sponsors and Collaborators
C. R. Bard
Principal Investigator: Robert J. Cerfolio, MD University of Alabama in Birmingham
Principal Investigator: Daniel L. Miller, MD WellStar Research Institute
  More Information

Responsible Party: C. R. Bard Identifier: NCT01394978     History of Changes
Other Study ID Numbers: NEO09-100
Study First Received: July 13, 2011
Results First Received: April 17, 2017
Last Updated: June 9, 2017

Keywords provided by C. R. Bard:
Pleural air leak
Pulmonary resection
Open thoracotomy processed this record on September 21, 2017